Received Mar 12, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | UNK | — |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | 7SS27 | — |
not received third dose; first dose on 21Oct2025 and a second dose on 26Dec2025; This non-serious case was reported by a nurse via call center representative and described the occurrence of incomplete course of vaccination in a 6-month-old female patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. Co-suspect products included Men ACWY-CRM NVS (Menveo) (batch number AH7Z3, expiry date 30-SEP-2026) and (batch number 7SS27, expiry date 31-OCT-2026) for prophylaxis. Concomitant products included MENINGOCOCCAL VACCINE A/C/Y/W CONJ (CRM197) (MENVEO). The patient did not receive the 3rd dose of Menveo. On 21-OCT-2025, the patient received the 1st dose of Menveo. On 21-OCT-2025, an unknown time after receiving Menveo, the patient experienced inappropriate age at vaccine administration (Verbatim: first dose on 21Oct2025 and a second dose on 26Dec2025). On an unknown date, the patient experienced incomplete course of vaccination (Verbatim: not received third dose). The outcome of the incomplete course of vaccination and inappropriate age at vaccine administration were not applicable. Additional Information: GSK Receipt Date: 04-MAR-2026 A registered nurse reported an infant was administered Menveo(1-Vial) vaccine first dose on 21-OCT-2025 and a second dose on 26-DEC-2025. The registered nurse stated they had ordered the Menveo (2-Vial) for the office and had reported the adverse events to the Vaccine Adverse Event Reporting System (VAERS). The registered nurse stated no adverse effects documented for the patient. The batch number was not provided upon follow- up with the reporter.; Sender's Comments: US-GSK-US2026029852:Same reporter/Different patient
MENVEO